Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03963895 · ClinicalTrials.gov registry record · Phase 2
Safety and Efficacy Study of AB002 (E-WE Thrombin) in End Stage Renal Disease Patients on Chronic Hemodialysis
A Phase 2 study, sponsored by Aronora.
- Completed
- Registry status
- Phase 2
- Development phase
- 40
- Enrollment target
NCT03963895 is a Phase 2 study that has completed, run by Aronora. The registered enrollment target is 40 participants.
The verdict
NCT03963895, a Phase 2 study, has completed, sponsored by Aronora.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 40 participants
- Enrollment target
Study Summary
This study evaluates the safety and efficacy of AB002 (E-WE thrombin) in patients with end stage renal disease on chronic hemodialysis. Two dose levels will be evaluated in two cohorts. Within each cohort the patients will be randomized to receive either AB002 (E-WE thrombin) or placebo (at a ratio of 2:1 active: placebo).
Interventions
- DRUG placebo
- DRUG AB002 Dose 1
- DRUG AB002 Dose 2
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 40 participants |
| Start Date | 2019-07-03 |
| Est. Completion | 2020-12-29 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03963895
The ClinicalTrials.gov registry entry for NCT03963895 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 40 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Aronora, which has 4 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which placebo is the first listed.
NCT03963895 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03963895 about?
NCT03963895 is a clinical study titled "Safety and Efficacy Study of AB002 (E-WE Thrombin) in End Stage Renal Disease Patients on Chronic Hemodialysis". This study evaluates the safety and efficacy of AB002 (E-WE thrombin) in patients with end stage renal disease on chronic hemodialysis. Two dose levels will be evaluated in two cohorts. Within each cohort the patients will be randomized to receive either AB002 (E-WE thrombin) or placebo (at a ratio ...
What is the current status of trial NCT03963895?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 40 participants. The study started on 2019-07-03. Estimated completion is 2020-12-29.
What interventions are being tested in trial NCT03963895?
The interventions under investigation include: placebo (DRUG), AB002 Dose 1 (DRUG), AB002 Dose 2 (DRUG).
Who is sponsoring clinical trial NCT03963895?
This trial is sponsored by Aronora, which has 4 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.